San Antonio, TX, USA, 6 June 2016
Trajan Scientific and Medical (Trajan) announces two advancements in the development of devices and components for nano-electrospray ionization mass spectrometry (nanoESI-MS), in collaboration with the University of Adelaide in Australia, and with Queen’s University and Université Laval in Canada.
Trajan and the University of Adelaide’s Institute for Photonics and Advanced Sensing (IPAS) have been awarded an A$0.5 million Australian Research Council (ARC) Linkage grant to create glass capillaries and tubes with advanced geometries to enhance the sensitivity of mass spectrometry.
While photonics has a long history of developing unique glasses for optical sensors, there has only been an embryonic investigation into adopting these glass fabrication processes for mass spectrometry.
By collaborating on new R&D projects, Trajan can take full advantage of its recent expansion of glass fabrication capabilities, now comprising advanced manufacturing facilities in Melbourne, Australia, as well as San Diego, USA, and its co-location within IPAS in Adelaide, Australia.
Significant enhancement of nanoESI-MS sensitivity in this fabrication work with IPAS is expected to accelerate progress in disease research, biomarker discovery and drug development.
Trajan and Queen’s University (Queen’s), Kingston, Canada, via PARTEQ Innovations, the University’s technology transfer organization, have established a framework to license Professor Richard Oleschuk group’s multi-lumen emitter tip technology developed in collaboration with Professor Younès Messaddeq of Université Laval’s Center for Optics, Photonics and Lasers (COPL), Québec City, Canada.
Queen’s, Université Laval and Trajan will collaborate to commercialize multi-lumen emitter tip technology and also undertake further research to develop the next generation of emitter tips for the mass spectrometry industry.
Mr Mike Bailey, General Manager of Trajan’s Precision Fluidic Solutions Business Unit said he was encouraged by the speed at which Trajan and its University partners have been able to execute on the evolution of the glass fabrication capabilities from photonics to the field of mass spectrometry.
“In less than nine months Trajan has moved from a hypothetical discussion with our academic partners to execute our first tangible collaboration in the development of a next generation of glass devices and components to enhance the sensitivity of electrospray mass spectrometry. We are now keen to see that enthusiasm translate into new products that benefit the mass spectrometry community” said Mr Bailey.
Prof. Richard Oleschuk said this is an example of the interesting things that can happen when you have people with expertise in separate fields work with one another, and each have access to cutting edge fabrication and instrumentation resources. It is gratifying to see an idea become both a research reality and great opportunity with a supportive commercial partner.”
Prof. Younès Messaddeq, head of the Canada Excellence Research Chair in Photonic Innovations at Université Laval, said that it is the remarkable synergy between the research teams at Queen’s University and Université Laval that has allowed the development of this novel technology over such a short period of time.
Press Release [PDF]
Media Contact Information
Trajan Scientific and Medical
44 (0) 1244 403 100
Photo courtesy of the University of Adelaide: IPAS Researcher Heike Ebendorff-Heidepriem loading a specially modified extrusion furnace.
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.